Last reviewed · How we verify
CAZ104
At a glance
| Generic name | CAZ104 |
|---|---|
| Also known as | CAZ104 (2000mg Ceftazidime/500mg Avibactam), CAZ104 (3000mg Ceftazidime/1000mg Avibactam) |
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens (PHASE3)
- Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections) (PHASE3)
- Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections) (PHASE3)
- A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects (PHASE1)
- A Study to Assess the Levels of Two Antibiotics in the Blood When Given Together and Separately (PHASE1)
- Study to Assess the Concentration of Avibactam and Ceftazidime in Epithelial Lining Fluid and Plasma (PHASE1)
- A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CAZ104 CI brief — competitive landscape report
- CAZ104 updates RSS · CI watch RSS
- Pfizer portfolio CI